The National Institutes of Health yesterday announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.

Trials will include hospitalized and non-hospitalized patients; the expected third trial will later focus on those discharged after hospitalization for moderate-to-severe disease.

NIH said research shows many COVID-19 patients who died suffered from blood clots throughout their bodies; these blood thinners, known as ACTIV-4 antithrombotics, could provide insights for care.

Related News Articles

Headline
The AABB, America’s Blood Centers and the American Red Cross Friday urged eligible individuals to donate blood, calling the nation’s blood supply “critically…
Headline
A new analysis by Global Health 50/50, an initiative to advance gender equality in global health, sheds light on sex disparities in COVID-19 deaths.…
Headline
The Department of Health and Human Services Friday announced the new option of saliva tests at federal community-based testing sites in areas experiencing…
Headline
Jim Skogsbergh, president and CEO of Advocate Aurora Health, will join AHA Board Chair Melinda Estes, M.D., Oct. 22 at 3:30 p.m. ET to discuss COVID-19’s…
Chairperson's File
COVID-19 is a pandemic with no precedent, and certainly no equal. In many ways, we’ve been learning as we go. For health care professionals, this has elevated…
Headline
A recent article on hospital field finances ignores the diverse experiences of hospitals during the pandemic, particularly those under significant financial…